Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia

BACKGROUND: Flavopiridol is a protein-bound, cytotoxic, cyclin dependent kinase inhibitor. A phase II trial of flavopiridol followed by ara-C and mitoxantrone with flavopiridol given by 1-h bolus for adults with newly-diagnosed, poor-risk acute myelogenous leukemia yielded 67% complete remission wit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Karp, Judith E., Garrett-Mayer, Elizabeth, Estey, Elihu H., Rudek, Michelle A., Smith, B. Douglas, Greer, Jacqueline M., Drye, D. Michelle, Mackey, Karen, Dorcy, Kathleen Shannon, Gore, Steven D., Levis, Mark J., McDevitt, Michael A., Carraway, Hetty E., Pratz, Keith W., Gladstone, Douglas E., Showel, Margaret M., Othus, Megan, Doyle, L. Austin, Wright, John J., Pagel, John M.
Formato: Artigo
Lenguaje:Inglês
Publicado: Ferrata Storti Foundation 2012
Materias:
Original Articles and Brief Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3487449/
https://ncbi.nlm.nih.gov/pubmed/22733022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.062539
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares